Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy
- 15 June 2022
- journal article
- editorial
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (3) , 593-595
Abstract
No abstract availableFunding Information
- National Institutes of Health
- National Cancer Institute (DR52-18)
- Damon Runyon Cancer Research Foundation
- Instituto de Salud Carlos III
- National Cancer Institute (R37CA230636)
- European Regional Development Fund (PI20/00260)
- Gobierno de Navarra (54-2021)
This publication has 12 references indexed in Scilit:
- NASH limits anti-tumour surveillance in immunotherapy-treated HCCNature, 2021
- Hepatocellular carcinomaNature Reviews Disease Primers, 2021
- Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of ErysipelotrichalesPLOS ONE, 2021
- Steatohepatitis Impairs T-cell–Directed Immunotherapies Against Liver Tumors in MiceGastroenterology, 2021
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinomaJournal of Hepatology, 2020
- Metformin enhances anti-mycobacterial responses by educating CD8+ T-cell immunometabolic circuitsNature Communications, 2020
- Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12Immunity, 2018
- Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockadeNature Medicine, 2018
- Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver DiseaseHepatology, 2018
- NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesisNature, 2016